CD19 and neoplasm: In a similar study, CRISPR /Cas9-mediated PDCD1 disruption increased the CD19-CAR-T cell cytotoxicity in vitro and improved CAR-T cell-mediated removal of tumor tissue in vivo in a xenograft tumor model [99].